参考文献/References:
[1] Masarone DLimongelli G,Ammendola E,et al. Risk stratification of sudden cardiac death in patients with heart failure:an update[J]. J Clin Med,2018,7(11):436.
[2] Desai AS,McMurray JJV,Packer M,et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients[J]. Eur Heart J,2015,36(30):1990-1997.
[3] Rohde LE,Chatterjee NA,Vaduganathan M,et al. Sacubitril/Valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart?failure cause[J]. JACC Heart Fail,2020,8(10):844-855.
[4] McMurray JJ,Packer M,Desai AS,et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure:rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J]. Eur J Heart Fail,2013,15(9):1062-1073.
[5] Xie W,Zheng F,Song X,et al. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction:Network meta-analysis[J]. Int J Cardiol,2016,205(205):65-71.
[6] Hubers SA,Brown NJ.Combined angiotensin receptor antagonism and neprilysin inhibition[J]. Circulation,2016,133(11):1115-1124.
[7] Ferrari R,Cardoso J,Fonseca MC,et al. ARNIs:balancing "the good and the bad" of neuroendocrine response to HF[J]. Clin Res Cardiol,2020,109(5):599-610.
[8] de Diego C,Gonzalez-Torres L,Nunez JM,et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices[J]. Heart Rhythm,2018,15(3):395-402.
[9] Martens P,Nuyens D,Rivero-Ayerza M,et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2019,108(10):1074-1082.
[10] El-Battrawy I,Pilsinger C,Liebe V,et al. Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients[J]. J Clin Med,2019,8(10):1582.
[11] Peng S,Lu XF,Qi YD,et al. LCZ696 ameliorates oxidative stress and pressure overload-induced pathological cardiac remodeling by regulating the Sirt3/MnSOD pathway[J]. Oxid Med Cell Longev,2020,2020:9815039.
[12] Iborra-Egea O,Gálvez-Montón C,Roura S,et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling:a systems biology approach[J]. NPJ Syst Biol Appl,2017,3(1):12.
[13] Burke RM,Lighthouse JK,Mickelsen DM,et al. Sacubitril/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts[J]. Circ Heart Fail,2019,12(4):e005565.
[14] Valentim Gon?alves A,Pereira-da-Silva T,Galrinho A,et al. Antiarrhythmic effect of sacubitril-valsartan:cause or consequence of clinical improvement?[J]. J Clin Med,2019,8(6):869.
[15] Okutucu S,Sabanoglu C,Yetis Sayin B,et al. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction[J]. Acta Cardiol,2020,75(1):20-25.
[16] Chang PC,Lin SF,Chu Y,et al. LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model[J]. Cardiovasc Ther,2019,2019:6032631.
[17] Chang PC,Wo HT,Lee HL,et al. Sacubitril/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model[J]. J Card Fail,2020,26(6):527-537.
[18] Okutucu S,Oto A. A electrical storm after initiating sacubitril/valsartan:arrhythmic paradox[J]. Cardiology,2019,142(1):24-25.
[19] Vicent L,Juarez M,Martin I,et al. Ventricular arrhythmic storm after initiating sacubitril/valsartan[J]. Cardiology,2018,139(2):119-123.
[20] Vicent L,Juarez M,Bruna V,et al. Clinical profile and ventricular arrhythmias after sacubitril/valsartan initiation[J]. Cardiology,2019,142(1):26-27.